Lunsekimig - Sanofi
Alternative Names: Anti-IL-13 and TSLP - Sanofi; Anti-IL-13/TSLP - Sanofi; SAR-443765Latest Information Update: 28 Jun 2025
At a glance
- Originator Sanofi
- Class Anti-inflammatories; Antiasthmatics; Monoclonal antibodies; Single-domain antibodies
- Mechanism of Action Interleukin 13 inhibitors; Thymic stromal lymphopoietin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Asthma; Atopic dermatitis; Rhinosinusitis
Most Recent Events
- 28 Jun 2025 No recent reports of development identified for phase-I development in Asthma(In adults) in Germany (IV)
- 28 Jun 2025 No recent reports of development identified for phase-I development in Asthma(In adults) in Germany (SC)
- 28 Jun 2025 No recent reports of development identified for phase-I development in Asthma(In adults) in United Kingdom (IV)